MedPath

A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

Not Applicable
Completed
Conditions
Herpes Simplex
HIV Infections
Registration Number
NCT00002084
Lead Sponsor
Glaxo Wellcome
Brief Summary

To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or \> 100 cells/mm3.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (46)

Univ of South Alabama

πŸ‡ΊπŸ‡Έ

Mobile, Alabama, United States

Univ of Arizona / Health Science Ctr

πŸ‡ΊπŸ‡Έ

Tucson, Arizona, United States

Combat Group

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Los Angeles County - USC Med Ctr

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Infectious Disease Med Group / Adult Immunology Clinic

πŸ‡ΊπŸ‡Έ

Oakland, California, United States

UCI Med Ctr

πŸ‡ΊπŸ‡Έ

Orange, California, United States

UCSD Med Ctr

πŸ‡ΊπŸ‡Έ

San Diego, California, United States

San Diego Naval Hosp

πŸ‡ΊπŸ‡Έ

San Diego, California, United States

ViRx Inc

πŸ‡ΊπŸ‡Έ

San Francisco, California, United States

UCSF - San Francisco Gen Hosp

πŸ‡ΊπŸ‡Έ

San Francisco, California, United States

Scroll for more (36 remaining)
Univ of South Alabama
πŸ‡ΊπŸ‡ΈMobile, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.